Cellular processes in sepsis

Swiss Medical Weekly

Volumn 138, Issue 43-44, 2008, Pages 629-634

  Rudiger, Alain ^a   Stotz, Martin ^b   Singer, Mervyn ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ST MARY S HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Inflammation; Mitochondrial dysfunction; Organ failure; Sepsis; Suspended animation

Indexed keywords

CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; CELL DEATH; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY EXPENDITURE; ENERGY YIELD; HIBERNATION; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; INFECTION; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; MICROCIRCULATION; MITOCHONDRION; MORBIDITY; MORTALITY; PATHOGENESIS; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TISSUE NECROSIS; VIRULENCE;

EID: 56249140826     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Schmid A, Pugin J, Chevrolet JC, Marsch S, Ludwig S, Stocker R, et al. Burden of illness imposed by severe sepsis in Switzerland. Swiss Med Wkly. 2004;134:97-102.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001;29:S109-16.
3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546-54.
4. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168:165-72.
5. Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grand S, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606-18.
6. Lin MT, Albertson TE. Genomic polymorphisms in sepsis. Crit Care Med. 2004;32:569-79.
7. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med. 1988;318:727-32.
8. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med. 2001;29:557-61.
9. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms and sepsis. Shock. 2005;24:300-12.
10. Annane D, Bellissant E, Cavaillon J-M. Septic shock. Lancet. 2005;365:63-78.
11. Bayir H. Reactive oxygen species. Crit Care Med. 2005;33:S498-501.
12. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032-7.
13. Ochoa JB, Makarenkova V. T lymphocytes. Crit Care Med. 2005;33:S510-3.
14. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood. 1999;94:3413-20.
15. Aird WC. Coagulation. Crit Care Med. 2005;33:S485-7.
16. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536-45.
17. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett. 2008;582:117-31.
18. Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness. Shock. 2007;28:384-93.
19. Beutler B. Innate immunity: an overview. Mol Immunol. 2004;40:845-59.
20. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004;5:975-9.
21. Leaver SK, Finney SJ, Burke-Gaffney A, Evans TW. Sepsis since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities. Crit Care Med. 2007;35:1404-10.
22. Cornell TT, Shanley TP. Signal transduction overview. Crit Care Med. 2005;33:S410-3.
23. Zingarelli B. Nuclear factor-kappaB. Crit Care Med. 2005;33:S414-6.
24. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 2004;430:257-63.
25. Levy RM, Prince JM, Billiar TR. Nitric oxide: a clinical primer. Crit Care Med. 2005;33:S492-5.
26. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res. 1994;28:34-9.
27. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med. 1999;27:913-22.
28. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
29. Watson D, Grover R, Anzueto A, Lorente J, Smithies M, Bellomo R, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004;32:13-20.
30. Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, et al. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med. 2004;32:1-12.
31. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163:316-21.
32. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis. 2008;8:32-43.
33. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. New England Journal of Medicine. 2003;348:138-50.
34. von Müller L, Klemm A, Durmus N, Weiss M, Suger-Wiedeck H, Schneider M, et al. Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis. 2007;196:1288-95.
35. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413-22.
36. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp. 2007;280:21-36:160-4.
37. Dyson A, Stidwill R, Taylor V, Singer M. Tissue oxygen monitoring in rodent models of shock. Am J Physiol Heart Circ Physiol. 2007;293:H526-33.
38. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early-goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368-77.
39. Hayes MA, Timmins AC, Yau E, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med. 1994;330:1717-22.
40. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med. 1995;333:1025-32.
41. De Backer D, Creteur J, Preiser J-C, Dubois M-J, Vincent J-L. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med. 2002;166:98-104.
42. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360:219-23.
43. Protti A, Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care. 2006;10:228.
44. Suliman HB, Carraway MS, Piantadosi CA. Postlipopolysaccharide oxidative damage of mitochondrial DNA. Am J Respir Crit Care Med. 2003;167:570-9.
45. Suliman HB, Carraway MS, Welty-Wolf KE, Whorton AR, Piantadosi CA. Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1. J Biol Chem. 2003;278:41510-8.
46. Suliman HB, Welty-Wolf KE, Carraway M, Tatro L, Piantadosi CA. Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. Cardiovasc Res. 2004;64:279-88.
47. Nisoli E, Tonello C, Briscini L, Carruba MO. Inducible nitric oxide synthase in rat brown adipocytes: implications for blood flow to brown adipose tissue. Endocrinology. 1997;138:676-82.
48. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Critical Care Medicine. 1999;27:1230-48.
49. Brun C, Munck O. Lesions of the kidney in acute renal failure following shock. Lancet. 1957;272:603-7.
50. Ayala A, Wesche-Soldato DE, Perl M, Lomas-Neira JL, Swan R, Chung CS. Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis. Novartis Found Symp. 2007;280:37-52, 160-4.
51. Padilla PA, Roth MB. Oxygen deprivation causes suspended animation in the zebrafish embryo. Proc Natl Acad Sci U S A. 2001;98:7331-5.
52. Blackstone E, Morrison M, Roth MB. H2S induces a suspended animation-like state in mice. Science. 2005;308:518.
53. Heusch G, Schulz R, Rahimtoola SH. Myocardial hibernation: a delicate balance. Am J Physiol Heart Circ Physiol. 2005;288:984-99.
54. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004;364:545-8.
55. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007;35:1599-608.
56. Singer M, Glynne P. Treating critical illness: The importance of first doing no harm. PLoS Med. 2005;2:e167.